RecruitingPhase 4NCT06814938
A Study of a Novel Precision Medicine Approach For Obesity
A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial
Sponsor
Mayo Clinic
Enrollment
135 participants
Start Date
Feb 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- \- Obesity (BMI ≥30 kg/m2) without or with controlled chronic conditions (e.g., controlled hypertension).
Exclusion Criteria9
- Weight changes greater than 3% in the previous 3 months
- History of bariatric surgery including lap band and bariatric endoscopy
- Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during the patient's lifetime, or any suicidal behavior in the last month.
- Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
- Any contraindication to FDA-approved GLP1R agonists
- A person who is pregnant or wanting to become pregnant
- Once the positive or negative cohort is filled at 2:1 ratio, some patients will be screen failed if their gene cohort is full.
- A family member who is enrolled in this study.
- Principal Investigator Discretion
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSemaglutide
2.4 mg subcutaneous weekly
DRUGPlacebo
Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06814938
Related Trials
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
NCT007393621 location
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT0667293940 locations
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT0667254950 locations
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433774 locations
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location